Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors.

MLA

Kalinkin, Alexey I., et al. “Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors.” International Journal of Molecular Sciences, vol. 24, no. 24, Dec. 2023, p. 17343. EBSCOhost, https://doi.org/10.3390/ijms242417343.

APA

Kalinkin, A. I., Sigin, V. O., Kuznetsova, E. B., Ignatova, E. O., Vinogradov, I. I., Vinogradov, M. I., Vinogradov, I. Y., Zaletaev, D. V., Nemtsova, M. V., Kutsev, S. I., Tanas, A. S., & Strelnikov, V. V. (2023). Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors. International Journal of Molecular Sciences, 24(24), 17343. https://doi.org/10.3390/ijms242417343

Chicago

Kalinkin, Alexey I., Vladimir O. Sigin, Ekaterina B. Kuznetsova, Ekaterina O. Ignatova, Ilya I. Vinogradov, Maxim I. Vinogradov, Igor Y. Vinogradov, et al. 2023. “Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors.” International Journal of Molecular Sciences 24 (24): 17343. doi:10.3390/ijms242417343.